Skip to content
Our Latest News, Case Studies, Webinars & More
What the new BIS 50% Rule Means for Third-Party Screening & Ownership Due Diligence
On September 29, 2025, the Bureau of Industry and Security of the US Department of Commerce (“BIS”) issued a new interim final rule [...]
The Importance of TPRM in Facilitating Ethical Transactions with HCPs
In the Life Sciences industry, maintaining ethical and transparent relationships with healthcare professionals (HCPs) is fundamental to trust, patient safety, and business integrity. [...]
Agility, Innovation & Strong (Ethical) Foundations
Earlier this month, Ethixbase360 was delighted to sponsor the third annual Risk & Compliance Pharma & Life Sciences Conference, held in London. [...]
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape The pharmaceutical and life sciences industry […]
Sonova
From manual to automated, Ethixbase360 accelerated and simplified the entire third-party compliance and due diligence process for Sonova, a leading […]
Pharma/ Life Sciences Industry Outlook 2023
Master the Dynamic Challenges of the Pharma Industry in 2023 The pharmaceutical industry faces complex regulatory challenges and scrutiny while […]
The Future of E-Governance and Anti-Corruption Efforts
Watch Recording Webinar Overview: In today’s complex and rapidly changing business environment, managing risk and ensuring compliance is more important […]
Extensive Questionnaire Will Uncover Lieferkettengesetz (SCDDA) Compliance Gaps
Official guidelines for Germany’s Supply Chain Due Diligence Act (SCDDA), or Lieferkettengesetz Act, are now available. Released on 14 October […]
